Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab + verteporfin photodynamic therapy in treatment-naive subfoveal CNV secondary to AMD
2007-006235-31Phase 2Completed
- Sponsor
- Fondazione G.B. Bietti-IRCCS
- Start
- Nov 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ranibizumab and verteporfin in age-related macular degeneration (AMD) and Subretinal neovascularization, sponsored by Fondazione G.B. Bietti-IRCCS. Primary endpoint: Mean change in best-corrected visual acuity at 12 months. Started Nov 2007; status: completed.
02
Drugs
ranibizumabverteporfin
03
Conditions
age-related macular degeneration (AMD)Subretinal neovascularization
Beyond the preview
Go deeper on 2007-006235-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006235-31.